Skip to search formSkip to main contentSkip to account menu
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
  • Y. WuC. Zhou Y. Zuo
  • Medicine, Biology
    Annals of oncology : official journal of the…
  • 1 September 2015
TLDR
It is demonstrated that first-line erlotinib provides a statistically significant improvement in PFS versus GP in Asian patients with EGFR mutation-positive NSCLC (NCT01342965).
View on PubMed
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study.
View on PubMed
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL,…
  • C. ZhouY. Wu C. You
  • Medicine, Biology
    Annals of oncology : official journal of the…
  • 1 September 2015
TLDR
The significant OS benefit observed in patients treated with EGFR-TKI emphasises its contribution to improving survival of EGFR mutation-positive advanced non-small-cell lung cancer patients, suggesting that erlotinib should be considered standard first-line treatment of EGfr mutant patients and EGFR -TKI treatment following first- line therapy also brings significant benefits to those patients.
View on PubMed
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
  • J. YangL. Sequist Y. Wu
  • Medicine, Biology
    Annals of oncology : official journal of the…
  • 1 November 2016
TLDR
Tolerability-guided dose adjustment is an effective measure to reduce afatinib-related AEs without affecting therapeutic efficacy in phase III LUX-Lung 3 and 6 trials.
View on PubMed
Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).
TLDR
Single-agent erlotinib was active and well tolerated in NSCLC patients with BM and had significantly longer median PFS versus EGFR wild-type disease.
View on PubMed
ROS1 fusions in Chinese patients with non-small-cell lung cancer.
TLDR
ROS1 fusion-negative patients may have a better survival than ROS2 fusion-positive patients, and lower pathological stage, younger age and ROS1 fused status were significantly associated with better prognosis on multivariate analysis.
View on PubMed
HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib
TLDR
Pyrotinib showed activity against NSCLC with HER2 exon 20 mutations in both patient-derived organoids and a PDX model and showed promising efficacy in the clinical trial.
View on Wolters Kluwer
Treatment outcome for patients with primary NSCLC and synchronous solitary metastasis
  • Q. XuY. Wang C. Zhou
  • Medicine, Psychology
    Clinical and Translational Oncology
  • 22 February 2013
TLDR
Aggressive local and metastasis treatments could lead to better clinical outcomes and thus provide an option for clinicians in the future management of patients with NSCLC and synchronous solitary metastasis.
View on Springer
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO,…
View on PubMed
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
In this prospective phase III trial, afatinib combined with paclitaxel improved progression-free survival and objective response, compared with single-agent chemotherapy, in patients with NSCLC who…
View PDF
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License